Latest Product Launches News

Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.

SunRice reported a 4% rise in net profit after tax for FY26 to $73.3 million, maintaining an 8% EBITDA margin despite a 2.5% revenue decline. The company declared a record fully franked dividend of 70 cents per share but expects FY27 profit to fall amid a smaller Australian rice crop.

The a2 Milk Company has announced a $300 million fully franked special dividend following regulatory clearance in China to rebrand infant formula products under its a2 label.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AoFrio Limited has successfully closed a renounceable pro-rata rights issue, securing NZ$4.428 million to fund its push into US and European markets and advance AI-driven innovations in cold drink equipment.

Osteopore Limited has completed another incremental drawdown of A$250,000 on the second tranche of its redeemable convertible notes, continuing its steady funding progress under a A$20 million subscription agreement with Advance Opportunities Fund.

The a2 Milk Company has clinched final Chinese regulatory approval to rebrand infant formula products under its flagship a2™ label, completing a pivotal acquisition step. The company plans to launch these products later in 2026 and is poised to declare a $300 million special dividend.

Peak Processing has reported three consecutive months of positive EBITDA and raised its Q4 FY26 beverage production guidance to approximately 1.6 million units, surpassing earlier estimates.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.